RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer

An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Sun Yat-sen University Cancer Center; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Sun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07103395, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Patients must have histologically or cytologically confirmed locally advanced, unresectable (Stage III) non-small cell lung cancer (NSCLC);

    Inclusion criterion 2

  3. Women of childbearing potential (WOCBP) must agree to use contraception during the study treatment and for 5 months after the last dose of study drug (i.e., 30 days [one ovulation cycle] plus approximately five half-lives of the study drug);

    Inclusion criterion 8

    History of another primary malignancy within 5 years prior to starting treatment, except for adequately treated basal or squamous cell carcinoma of the skin or cancer of the cervix in situ and the disease under study;

    Exclusion criterion 12

    Current or prior use of immunosuppressive medication within 28 days before the first dose of Iparomlimab and tuvonralimab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid. Systemic steroid administration required to manage toxicities arising from radiation therapy delivered as part of the chemoradiation therapy for locally advanced NSCLC is allowed.

    Exclusion criterion 28

    Any unresolved toxicity CTCAE >Grade 2 from the prior chemoradiation therapy will be excluded from randomization;

    Exclusion criterion 29

    Patients with Grade ≥2 pneumonitis from prior chemoradiation therapy will be excluded from randomization;

    Exclusion criterion 30

    Any prior Grade ≥3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE>Grade 1.

    Exclusion criterion 31

  4. WHO Performance Status (PS) score of 0 or 1;

    Inclusion criterion 6

    World Health Organization (WHO) Performance Status of 2-4;

    Exclusion criterion 17

  5. EGFR, ALK, and ROS1 wild-type;

    Inclusion criterion 3

    Absolute neutrophil count ≥ 1.5 × 10⁹/L;

    Inclusion criterion 11

    Platelets ≥ 100 × 10⁹/L;

    Inclusion criterion 12

    Hemoglobin ≥ 9.0 g/dL;

    Inclusion criterion 13

    Creatinine clearance ≥ 50 mL/min as calculated by the Cockcroft-Gault formula (Cockcroft and Gault, 1976);

    Inclusion criterion 14

    Serum bilirubin ≤ 1.5 × upper limit of normal (ULN);

    Inclusion criterion 15

    AST and ALT ≤ 2.5 × ULN.

    Inclusion criterion 16

    Absolute neutrophil count <1.5 x 109/L (1500 per mm3)

    Exclusion criterion 20

    Platelets <100 x 109/L (100,000 per mm3)

    Exclusion criterion 21

    Haemoglobin<9.0 g/dL (5.59 mmol/L)

    Exclusion criterion 22

    Serum creatinine CL <50 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976)

    Exclusion criterion 23

    Serum bilirubin >1.5 x upper limit of normal (ULN).

    Exclusion criterion 24

    Aspartate Transaminase(AST) and Alanine Transaminase(ALT) >2.5 x ULN.

    Exclusion criterion 25

  6. Mixed small cell and non-small cell lung cancer histology;

    Exclusion criterion 3

  7. Female subjects must not be breastfeeding;

    Inclusion criterion 7

    Female patients who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control.

    Exclusion criterion 13

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07103395, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Males or females aged 18 to 75 years or older;
  • Patients must have histologically or cytologically confirmed locally advanced, unresectable (Stage III) non-small cell lung cancer (NSCLC);
  • EGFR, ALK, and ROS1 wild-type;
  • No prior chemotherapy, radiotherapy, surgery, targeted therapy, or immunotherapy;
  • Expected survival ≥ 12 weeks;
  • WHO Performance Status (PS) score of 0 or 1;
  • Female subjects must not be breastfeeding;
  • Women of childbearing potential (WOCBP) must agree to use contraception during the study treatment and for 5 months after the last dose of study drug (i.e., 30 days [one ovulation cycle] plus approximately five half-lives of the study drug);
  • Adequate organ and bone marrow function as defined by the following criteria:
  • Forced Expiratory Volume in 1 second (FEV1) ≥ 800 mL;
  • Absolute neutrophil count ≥ 1.5 × 10⁹/L;
  • Platelets ≥ 100 × 10⁹/L;
  • Hemoglobin ≥ 9.0 g/dL;
  • Creatinine clearance ≥ 50 mL/min as calculated by the Cockcroft-Gault formula (Cockcroft and Gault, 1976);
  • Serum bilirubin ≤ 1.5 × upper limit of normal (ULN);
  • AST and ALT ≤ 2.5 × ULN.

Exclusion Criteria:

  • Exclusion criteria for enrolment for neoadjuvant therapy. Patients should not enter the study if any of the following exclusion criteria are fulfilled:
  • Concurrent enrolment in another clinical study, unless it is an observational(non-interventional) clinical study;
  • Mixed small cell and non-small cell lung cancer histology;
  • Prior use of anti-PD-1, anti-PD-L1, or anti-CTLA4 antibodies;
  • Recent major surgery within 4 weeks prior to entry into the study (excluding the placement of vascular access;
  • Active or prior documented autoimmune disease within the past 2 years;
  • Active or prior documented inflammatory bowel disease (eg. Crohn's disease, ulcerative colitis);
  • History of primary immunodeficiency;
  • History of organ transplant that requires therapeutic immunosuppression;
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses including any patient known to have hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the patient to give written informed consent;
  • Known history of tuberculosis;
  • History of another primary malignancy within 5 years prior to starting treatment, except for adequately treated basal or squamous cell carcinoma of the skin or cancer of the cervix in situ and the disease under study;
  • Female patients who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control.
  • Exclusion criteria for concurrent chemoradiation following neoadjuvant therapy. Patients should not enter the concurrent chemoradiation phase if any of the following exclusion criteria are fulfilled:
  • Patients who develop distant metastasis;
  • Patients who develop locoregional disease progression and the irradiation dose of normal tissue will exceed the limit.
  • World Health Organization (WHO) Performance Status of 2-4;
  • Inadequate organ and marrow function as defined below:
  • Forced expiratory volume in 1 second (FEV1) <800ml
  • Absolute neutrophil count <1.5 x 109/L (1500 per mm3)
  • Platelets <100 x 109/L (100,000 per mm3)
  • Haemoglobin<9.0 g/dL (5.59 mmol/L)
  • Serum creatinine CL <50 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976)
  • Serum bilirubin >1.5 x upper limit of normal (ULN).
  • Aspartate Transaminase(AST) and Alanine Transaminase(ALT) >2.5 x ULN.
  • Further exclusion criteria for consolidation therapy. Patients should not enter the consolidation therapy if any of the following exclusion criteria are fulfilled:
  • Patients who have progressed whilst definitive platinum based, concurrent chemoradiation therapy;
  • Current or prior use of immunosuppressive medication within 28 days before the first dose of Iparomlimab and tuvonralimab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid. Systemic steroid administration required to manage toxicities arising from radiation therapy delivered as part of the chemoradiation therapy for locally advanced NSCLC is allowed.
  • Any unresolved toxicity CTCAE >Grade 2 from the prior chemoradiation therapy will be excluded from randomization;
  • Patients with Grade ≥2 pneumonitis from prior chemoradiation therapy will be excluded from randomization;
  • Any prior Grade ≥3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE>Grade 1.

Quoted from ClinicalTrials.gov, NCT07103395, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07103395, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07103395